Abstract Library

#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience

Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Smiroldo V

Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, Zerbi A,

Keywords: bone metastases, skeletal related event, survival, bisphosphonates, 68Ga-PET, 18FDG-PET, CT scan,

#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Armeni E, Hayes A, Gopaul A, Aristidou I, Navalkissoor S,

Keywords: bone metastases, NEN, zoledronic acid, skeletal related event,

#2791 NEN Skeletal Metastasis Performance and the Correlation with Cell Proliferation: 112 Cases of 68Ga-DOTA-TATE Results Analysis

Introduction: 68Ga-DOTA-TATE PET/CT plays an important role in neuroendocrine neoplasm(NEN)diagnosis and biological charecteristcs evaluation.Skeleton is the second common metastatic organ in NEN after liver and it affects the quality of patient’s life.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yu J

Authors: Xie Q, Lu M, Li J, Li N, Yang Z,

Keywords: Neuroendocrine neoplasm, somatostatin receptor, PET/CT, Skeletal metastasis,

#2213 Imaging Modality Depending on the Levels of Tumor Markers

Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Iorio J

Authors: Iorio J, Eleta M, Cuneo L, Polillo D, Peña F,

Keywords: neuroendocrine tumors, tumor marker, 18F-FDOPA, PET/CT,

#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)

Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rizzo F, Vesely C, Childs A, Mandair D, Khan M,

Keywords: CTC, CXCR4, bone,